{"id":"quadratus-triamcinolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy (with topical use)"},{"rate":null,"effect":"Hypothalamic-pituitary-adrenal (HPA) axis suppression"},{"rate":null,"effect":"Immunosuppression and increased infection risk"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis (with chronic systemic use)"},{"rate":null,"effect":"Mood changes and insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. This results in reduced immune cell infiltration and suppression of both humoral and cell-mediated immune responses. The drug is commonly used in topical, intralesional, or systemic formulations depending on the therapeutic indication.","oneSentence":"Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:29.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and allergic skin conditions"},{"name":"Rheumatoid arthritis and other inflammatory joint diseases"},{"name":"Asthma and allergic respiratory conditions"},{"name":"Autoimmune and inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT03407027","phase":"PHASE4","title":"Efficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome","status":"UNKNOWN","sponsor":"Hospital de Braga","startDate":"2017-11-01","conditions":"Low Back Pain","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Quadratus lumborum infiltration with triamcinolone."],"phase":"marketed","status":"active","brandName":"Quadratus triamcinolone","genericName":"Quadratus triamcinolone","companyName":"Hospital de Braga","companyId":"hospital-de-braga","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and allergic skin conditions, Rheumatoid arthritis and other inflammatory joint diseases, Asthma and allergic respiratory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}